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Currently no available immunoassay system offers
complete protection against spuriously elevated or
lowered results due to interference by Human Anti-
Mouse Antibodies (HAMA). Although routine use of
chromatography procedures is not an acceptable op-
tion because of the extra cost and workload involved,
such a procedure would be highly desirable to ensure
accurate immunoassay results. The present report de-
scribes a relatively simple affinity chromatography
procedure using a HiTrap Protein G column to isolate
immunoglobulin G (IgG) HAMA, followed by a HiTrap
N-hydroxy-succinimide(NHS)-activated column cou-
pled to goat-anti human immunoglobulin M (IgM) to
bind IgM HAMA. To examine the usefulness of this pur-
ification procedure we determined CA 125 in forty
serum samples prior to and following chromatogra-
phy. Pre- and post-injection samples were obtained
from 20 patients injected with 1 mg of 111In-Iabelled
murine OC 125 F(ab’)2 fragments in an immunoscintig-
raphy study.
It is shown that this analytical procedure provides a
technique to determine the extent and the nature of
the existing HAMA interference in samples of patients
after in vivo use of monoclonal antibodies for diagnos-
tic or therapeutic purposes. The procedure can also
contribute to the clarification of clinically discordant
CA 125 results. Finally, the availability of such a proce-
dure in the clinical laboratory provides an opportunity
to test the robustness of newly developed immunoas-
say systems towards HAMA interference.
Key words: Human Anti-Mouse Antibodies (HAMA);
CA 125; Chromatography; Heterophilic antibody inter-
ference.
Introduction
Heterophilic antibodies comprise human immuno-
globulins directed against antigenic determinants from
non-human species. Agents causing development of
such heterophilic antibodies may originate either from
natural sources (like nutritional or agricultural factors)
or following injection of mouse monoclonal antibodies
for diagnostic or therapeutic purposes, the latter pos-
sibly leading to development of Human Anti-Mouse
Antibodies (HAMA) (1–3). The development of HAMA
is well known to influence both in vivo and in vitro di-
agnostic applications of monoclonal antibodies. For in-
stance, diagnostic testing kits designed for the quanti-
tation of tumour markers in serum are not guaranteed
against unexpected interferences emerging from
HAMA present in the serum samples under considera-
tion. Consequently, many attempts have been under-
taken to develop analytical procedures to eliminate
these undesired interferences caused by HAMA
present in a given specimen. At least four different ap-
proaches have been reported, each of which has limita-
tions in terms of general applicability, laboriousness,
or costs. The most widely used methods to protect as-
say systems from HAMA interference are:
1. the addition of blocking reagents (i. e., whole murine
serum or immunoglobulins) to the incubation me-
dium (4, 5);
2. the development of heterologous double determi-
nant two step sandwich type immunoassays using
different monoclonal or polyclonal antibodies as
capture and tracer (6);
3. the combination of non-murine polyclonal with mu-
rine monoclonal antibodies in a single assay (7–9);
and
4. the removal of HAMA by chromatography (10, 11).
The first three methods have been used to a certain ex-
tent in the development of the second generation CA
125 assay systems. However, HAMA interferences can
still occur (12). Chromatography of serum specimens
before immunoassay could be used to circumvent this
problem of incomplete protection against HAMA (10,
11), but such a procedure should preferably be simple.
Thus, we developed a straightforward chromatogra-
phy procedure which can be used
1. to determine the extent of HAMA response in serum
specimens with unexpected or clinically unex-
plained immunoassay results and
2. to test the robustness of newly developed assay
systems against HAMA interferences.
The aim of the present report is to describe this rela-
tively simple chromatography procedure and to illus-
trate its use by presenting results from patients who
were participating in an immunoscintigraphy study.
The availability of such a procedure in a clinical tumour
marker laboratory is of growing importance consider-
ing the possible increase in the occurrence of HAMA
positive serum samples due to increased clinical appli-
cation of murine antibodies (5).
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Patients and Methods
Patients
Patients suspected of having ovarian cancer were injected iv
with 1 mg of 111In-labelled murine OC 125 F(ab’)2 fragments,
the monoclonal antibody against the CA 125 determinant, in
an immunoscintigraphy study. Blood samples were taken
prior to, as well as three or more weeks after, injection and
centrifuged for 10 minutes at 2000 x g. Serum specimens were
stored at –35 °C until assayed. For the present study serum
samples from 20 patients were used, of whom ten patients
demonstrated HAMA development following injection of the
antibody fragment.
Methods
CA 125 was determined in all specimens using two different
assay procedures. The first assay used was the Abbott CA 125
RIA (Abbott Laboratories, Chicago, IL, USA). This was a dou-
ble determinant ’sandwich-type’ immunoradiometric assay
using OC 125 mouse monoclonal antibody coated beads as
capture and 125I-labelled OC 125 mouse monoclonal antibody
as tracer. The kits were used according to the manufacturer’s
instructions. The assay system was identical to the ’first
generation’ Centocor RIA I assay system, and was partly pro-
tected against HAMA interference. This assay system was
widely used until it was replaced by the ’second generation’
CA 125 II system. The minimum detectable concentration of
this assay was determined to be 7.6 kU/I. As a measure of pre-
cision we calculated the within- (CVw) and between-assay
(CVb) coefficients of variation for means of duplicate measure-
ments from a pool of serum in 15 consecutive assay runs. At a
mean serum concentration of 50 kU/I, the Abbott CA 125 RIA
demonstrated a CVw of 7.1 % and a CVb of 11 %.
The second assay used was an OC 125 F(ab’)2-based double
determinant ’sandwich-type’ immunoradiometric assay using
OC 125 F(ab’)2 (mouse) coated microtitreplate wells as capture
site and 125I-labelled OC 125 F(ab’)2 as a tracer. No attempt was
made to protect this assay from HAMA interference. This as-
say was developed in this laboratory (’In-House’(IH)) and the
procedure was essentially the same (except for label and anti-
body) as described previously by Boerman et al. (13). This as-
say will be referred to as the ’IH CA 125 RIA’. In brief, 100 µl of
serum, 100 µl of phosphate buffered saline (42 mmol of
Na2HPO4·2H20, 7.9 mmol of K2HPO4 (pH 7.35), 154 mmol NaCl,
5.0 g of acid free bovine albumin, and 31 mmol of NaN3 per li-
tre), and 10 µl of 125I-labelled OC 125 F(ab’)2 (600 µg/l) as a
tracer were added to 125I-labelled OC 125 F(ab’)2-coated 12-
well strips (Immulon-1 removawell strips, Dynatech Laborato-
ries, Chantilly, VA, USA). After overnight incubation at room
temperature the wells were washed three times and after
breaking off each well from the microtitre strip 125I-radioactiv-
ity was measured in each well in a g -scintillation counter (Wal-
lac Oy, Turku, Finland). We determined 7.0 kU/I as the lower
detection limit of IH CA 125 RIA in our laboratory. After meas-
urement of a serum pool (mean: 48 kU/I) in 15 consecutive as-
say runs, the CVw for means of duplicate measurements was
8.1 % and the corresponding CVb 15 %.
To calibrate the IH CA 125 RIA assay we constructed a stan-
dard curve using the CA 125 standard material included in the
Abbott CA 125 RIA. Comparison of the results of the two assay
systems was made by calculation of the regression line ac-
cording to Passing & Bablok (14). Using fifteen serum samples
in the concentration range between 7.0 and 17000 kU/I tho fol-
lowing regression equation was found:
IH CA 125 RIA = 0.994 x Abbott CA 125 RIA + 0.022 kU/I.
Prior to chromatography, all samples were assayed with the
two assay systems used. Next, affinity chromatography was
performed to isolate HAMA and to determine the subclass
(IgG and/or IgM) of the HAMA present in the specimen. The
flow-chart of the HAMA isolation by affinity chromatography
is shown in Figure 1. After each chromatography step CA 125
activity was determined in the effluent fraction as well as in
the eluted fraction by using the IH CA 125 RIA. To isolate the
IgG fraction a HiTrap Protein G column (1 ml, Pharmacia, Upp-
sala, Sweden) was used. In brief, 250 µl of serum and 250 µl of
0.02 mol phosphate buffer, pH 7.0, were applied to the HiTrap
Protein G column. Using the same phosphate buffer, a total ef-
fluent fraction was collected at a flow rate of 0.5 ml/min. Due
to the 4-fold sample dilution of the effluent fraction, the CA
125 concentrations as determined with the IH CA 125 RIA 
assay could be quantitated with a minimum detectable con-
centration of 28 kU/I. The bound IgG was eluted with 1 ml of
0.1 mol glycine-HCl buffer (pH 2.7). Immediately after elution
the pH was neutralized using 50 µl of 1 mol Tris-HCl (pH 9.0).
The isolated IgG HAMA in the 4.2-fold diluted eluent fraction
was quantitated in terms of apparent CA 125 concentrations
as measured with the IH CA 125 RIA. Thus, the minimal detect-
able concentration of IgG HAMA as determined with the IH CA
125 RIA was 29 kU/I.
Next, 500 µl of the Protein G column effluent fraction were
applied to a goat-anti-human IgM coupled, HiTrap NHS-acti-
vated column (1 ml, Pharmacia, Uppsala, Sweden), according
to the manufacturer’s instructions. Using the same phosphate
buffer as for the development of the Protein G column, a total
effluent fraction of 1 ml was collected at a flow rate of 
0.5 ml/min. Due to an 8-fold sample dilution, the minimum de-
tectable concentration of IH CA 125 RIA in the final effluent
was 56 kU/I. The bound IgM was eluted using the same proce-
dure as described for IgG. The IgM HAMA present in this elu-
tion fraction could be determined with a minimum detectable
concentration of 59 kU/I by using the IH CA 125 RIA, and is ex-
pressed in terms of apparent CA 125. The IH CA 125 RIA deter-
minations in all the eluent and effluent fractions were done us-
ing 100 µl of such a fraction together with 100 µl of foetal calf
serum (Hyclone Laboratories, Logan, UT, USA) to compensate
for the lack of a serum matrix. The accuracy of the affinity
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Fig. 1 Flow-chart of Human Anti-Mouse Antibodies (HAMA)
isolation by affinity chromatography.
Serum specimen
prior/after injection of OC 125 F(ab’)2
Abbott CA 125 RIA = ...
IH CA 125 RIA = ...
HiTrap Protein-G column
(Pharmacia)
Passage fraction
CA 125 and/or IgM HAMA
IH CA 125 RIA = ...
Goat Anti-Human IgM
HiTrap NHS-activated column
(Pharmacia)
Passage fraction
containing CA 125
IH CA 125 RIA = ...
Eluted fraction
containing IgM HAMA
IH CA 125 RIA = ...
Eluted fraction
containing IgG HAMA
IH CA 125 RIA = ...
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chromatography procedure was tested by calculating the pro-
cedural losses over the entire chromatographic work up. In
the case of nine pre-treatment (i. e. HAMA-free) samples the
mean recovery percentage of the IH CA 125 RIA results after
chromatography was calculated to be 70 % (SD = 12 %). Test-
ing of ten HAMA-negative postinjection serum samples re-
vealed a mean recovery of 68 % (SD = 24 %).
The results are grouped according to the IH CA 125 RIA con-
centrations as measured after completion of the two chroma-
tography steps, depending on the presence of detectable 
CA 125 and/or IgG or IgM HAMA. To summarize the data and
quantify the extent of HAMA interference, several ratios were
calculated and the mean ratios and their 95 % confidence
intervals (95 % CI: mean ± 1.96 x SE) are presented. We first
calculated the ratio of CA 125 Abbott and IH determinations
prior to chromatography (ratio of ’gross’ concentrations) to
assess the influence of HAMA on assay results obtained with
the two CA 125 assay systems used. This ratio depicts the
comparability of both assay systems. After removal of IgG
and/or IgM HAMA by chromatography ’net’ IH CA 125 concen-
trations were determined. To quantify the HAMA interference
the Abbott-gross/IH-net ratio and the IH-gross/IH-net ratio
were calculated. A higher ratio indicates a larger interference
by HAMA because the net concentrations determined after
chromatography are lower compared to the gross concentra-
tions determined before HAMA removal by chromatography.
Results
Tables 1 and 2 depict all assay results, which are
grouped according to the presence of detectable 
CA 125 and/or HAMA, as determined with the IH CA 125
RIA assay after the two chromatography steps.
The calculated mean CA 125 Abbott-gross/IH-gross
ratio of the specimens with no detectable HAMA 
(tab. 1; groups 1 and 2) was 1.16 (95 % CI: 1.02–1.30),
while the mean Abbott-gross/IH-net ratio was 1.69 
(95 % CI: 1.38–2.0). Thus, on average the Abbott CA 125
results were somewhat higher compared to the IH CA
125 RIA results. The higher ratio after chromatography
was due to lower IH-net results. This could also be in-
ferred from the IH-gross/IH-net ratio which was 1.46 
(95 % CI: 1.26–1.66) with these samples. All specimens
comprising group 1 showed detectable CA 125 concen-
trations after chromatography, meaning that these are
true positive CA 125 results. However, no CA 125 could
be detected after chromatography in the five samples
comprising group 2. However, this may be due to the
increased limit of detection caused by the dilution
steps of the chromatography procedure. Neither IgG
nor IgM HAMA above the minimum detectable concen-
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Patient Week Prior to After IgG column After IgM column
No. chromatography chromatography chromatography
(’gross’)1 (’net’)2, 3
Abbott RIA IH RIA IH RIA IH RIA
CA 125 CA 125 CA 125 IgG HAMA CA 125 IgM HAMA
Group 1: Detectable CA 125 but no detectable HAMA after chromatography
1 3 120 170 110 < 29 88 < 59
1 6 380 210 140 < 29 120 < 59
2 –1 2900 2200 > 20004 < 29 1700 < 59
2 3 150 170 96 < 29 90 < 59 
2 6 340 410 200 < 29 240 < 59
3 –1 3000 2400 1500 < 29 1600 < 59
3 3 2800 2100 1300 < 29 1400 < 59
3 6 3000 2200 990 < 29 750 < 59
6 –1 300 190 160 < 29 110 < 59
7 –1 1300 1300 1200 < 29 1200 < 59
7 3 400 210 140 < 29 190 < 59
8 –1 390 390 300 < 29 260 < 59
8 3 360 330 300 < 29 210 < 59
9 –1 1100 900 780 < 29 420 < 59
10 –1 1400 1400 1200 < 29 940 < 59
13 –1 14000 17000 9200 < 29 9800 < 59
15 7 190 140 140 < 29 110 < 59
20 –1 170 190 120 < 29 160 < 59
20 5 370 390 280 < 29 390 < 59
Group 2: No detectable CA 125 and no detectable HAMA after chromatography
15 –1 89 68 40 < 29 < 56 < 59
15 4 76 76 39 < 29 < 56 < 59
16 –1 43 64 41 < 29 < 56 < 59
19 2 31 34 < 28 < 29 < 56 < 59
19 9 45 28 < 28 < 29 < 56 < 59
1 Abbott-gross/IH-gross ratio: n = 24, mean = 1.16 (95 % CI: 1.02–1.30) 3 IH-gross/IH-net ratio: n = 24, mean = 1.46 (95 % CI: 1.26–1.66)
2 Abbott-gross/IH-net ratio: n = 24, mean = 1.69 (95 % CI: 1.38–2.0) 4 Too little specimens available for reanalysis after dilution
Tab. 1 CA 125 results of serum specimens in which no IgG or
IgM HAMA could be determined (above the minimum detect-
able concentrations) following chromatography. Specimens
were collected pre-injection (week -1) and several weeks post-
injection of 111In-labelled murine OC 125 F(ab’)2 fragments. All
determinations are expressed in kU/I.
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trations was found in either of these samples in groups
1 and 2. Thus, the CA 125 concentrations from these
samples could be considered accurate results.
The two groups in which HAMA was present (Tab. 2:
groups 3 and 4) showed an Abbott-gross/IH-gross ratio
of 0.29 (95 % CI: 0.19–0.39). This low ratio results from
the much higher apparent CA 125 values determined
with the HAMA-unprotected IH assay as compared to
the Abbott assay results, which is (at least partly)
HAMA protected. The Abbott-gross/IH-net ratio deter-
mined after chromatography was as high as 31 (95 %
CI: 0–63) illustrating unequivocal interference of the
Abbott CA 125 results by the presence of IgG and IgM
HAMA. Likewise, the IH-gross/IH-net ratio was raised to
102 (95 % CI: 14–190). In the samples comprising group
3, CA 125 could still be detected after chromatography.
The CA 125 activity originating from the IgG and IgM
fractions present in the sample, however, did account
for most of the CA 125 measured before chromatogra-
phy. This was even more prominent in the serum spec-
imens comprising group 4. After chromatography,
these samples did not demonstrate any CA 125 activity
above the minimum detection limit. Instead, all of the
signal could be attributed to IgG and IgM HAMA
present in these specimens.
Discussion
The application of murine monoclonal antibodies in
immunodiagnostic assay systems necessitates the de-
velopment of methods to eliminate or circumvent the
undesirable interference of heterophilic antibodies.
Such interferences may otherwise lead to undesirable
clinical consequences such as the discontinuation of
chemotherapy for ovarian cancer, or the initiation of a
procedure to determine the site and extent of sus-
pected recurrent tumour growth.
A recent report by Reinsberg discussed the subopti-
mal efficacy of three blocking reagents to eliminate
interferences caused by HAMA in a two-site immu-
noassay system (5). This author showed that it was dif-
ficult to suppress all spurious increases of CA 125 by
absorption of HAMA to non-specific mouse IgG or
other immunoglobulin preparations. Other studies
have investigated the degree of protection against
HAMA interferences attained by the development of
non-OC 125 antibodies, e. g. the Truquant B43.13 and
B27.1 monoclonal antibodies applied in the Truquant
OV2 (6), or the monoclonal antibody M11, applied in
the heterologous ’second generation’ CA 125 assays of
various formats (7–9). These reports invariably show
that it is still possible to end up with falsely elevated or
lowered results, especially when one-step protocols
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Patient Week Prior to After IgG column After IgM column
No. chromatography chromatography chromatography
(’gross’)1 (’net’)2, 3
Abbott RIA IH RIA IH RIA IH RIA
CA 125 CA 125 CA 125 IgG HAMA CA 125 IgM HAMA
Group 3: Detectable CA 125 and detectable HAMA after chromatography
5 3 1700 33000 2400 4800 730 540
6 3 >50004 33000 2400 17000 190 920
11 3 68000 150000 3400 25000 290 590
11 6 44000 130000 1700 27000 290 1300
13 3 18000 32000 15000 110 14000 250
13 6 22000 38000 22000 970 15000 700
14 3 270 1600 1200 430 61 220
16 4 2300 16000 8600 1500 1800 2600
16 6 5000 nd 16000 5600 1800 3600
17 4 1000 nd 6800 3700 170 1800
18 11 330 960 590 82 170 67
Group 4: No detectable CA 125 but detectable HAMA after chromatography
4 3 2300 4500 290 1300 < 56 290
12 3 290 1700 2000 420 < 56 290
12 6 200 1000 1100 180 < 56 220
14 6 430 1200 260 650 < 56 < 59
18 3 54 2300 540 150 < 56 290
1 Abbott-gross/IH-gross ratio: n = 14, mean = 0.29 3 IH-gross/IH-net ratio: n = 14, mean = 102 (95 % CI: 14–190)
(95 % CI: 0.19–0.39) 4 Too little specimens available for reanalysis after dilution
2 Abbott-gross/IH-net ratio: n = 16, mean = 31 (95 % CI: 0–63) nd Not done
Tab. 2 CA 125 results of serum specimens in which IgG and/
or IgM HAMA could be determined (above the minimum de-
tectable concentrations) following chromatography. Speci-
mens were collected pre-injection (week -1) and several weeks
post-injection of 111In-labelled murine OC 125 F(ab’)2 frag-
ments. All determinations are expressed in kU/I.
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are being used (9, 15). The development of assay
systems containing non-murine (polyclonal) antibod-
ies, e. g. Abbott IMx CA 125 containing sheep polyclon-
al antibodies, also did not prove to offer absolute pro-
tection from HAMA interference (6, 12).
The use of affinity chromatography procedures has
been described previously (10, 11). This approach re-
sulted in adequate separation of CA 125 and HAMA.
However, considerable disadvantages such as sample
dilution, additional workload, and higher costs, were
also recognised (11). The presently described chroma-
tography procedure also has some of these drawbacks.
Due to sample dilution the minimal detectable concen-
tration for IH CA 125 measurements is 4-fold increased
after the first chromatography step and 8-fold follow-
ing the second step. The minimal detectable concentra-
tions for the IgG and IgM HAMA activity measured by
the IH CA 125 RIA are slightly higher due to the elution
process. As a result, relatively low IH CA 125 concentra-
tions (i. e. < 56 kU/I) such as those in group 2 could not
be quantified exactly after two chromatography steps.
In these samples no HAMA could be determined either.
This was in contrast to group 4 (tab. 2), in which CA 125
concentrations were below the detection limit, but sub-
stantial HAMA concentrations were present. The re-
sults of groups 3 and 4 also showed that the Abbott RIA
did not accurately measure CA 125 concentrations in
HAMA-positive samples. Furthermore, seven samples
of the specimens with no detectable HAMA (Tab. 1,
group 1) showed higher IH CA 125 results after the sec-
ond (IgM) chromatography procedure compared to the
results after the first IgG chromatography step. In addi-
tion, two samples in group 4 (patient 12) had higher IH
CA 125 results after IgG chromatography compared to
the results obtained before chromatography. These
findings might be attributed to analytical imprecision
due to dilution, rounding off of analytical results to two
significant figures, serum matrix effects, or to changing
reaction kinetics of the various HAMA forms during the
analytical workup procedure. However, considering
the measured concentrations in these samples there is
little chance that this imprecision would have resulted
in a different clinical interpretation. The clinical rele-
vance of information about the exact nature of the
HAMA present (IgG or IgM) is probably rather limited.
In the present studies all samples in which IgM HAMA
could be determined also showed IgG HAMA. One
sample (group 4, patient 14) only showed IgG HAMA.
Moreover, IgG HAMA concentrations exceeded IgM
HAMA concentrations in all but four cases. One may in-
fer from these findings that IgG chromatography will
be sufficient to demonstrate the presence of HAMA in a
serum sample. This would enable serum CA 125 quan-
titations as low as 28 kU/I. However, best quantitations
of the serum CA 125 concentration are obtained after
removal of all HAMA, including IgM type HAMA, al-
though this can only be achieved at the cost of an in-
creased minimum detectable concentration.
One final point to address here is that only anti-idio-
typic HAMA is being considered in the present study.
None of the pre-injection samples showed detectable
HAMA. Moreover, both the in vivo applied monoclonal
antibody as well as the monoclonal antibody used in
the IH assay system were OC 125 F(ab’)2 based. With-
out the Fc domain present, it is unlikely that anti-iso-
typic HAMA has played an important role in the present
study.
In conclusion, the chromatography procedure de-
scribed in the present study does provide a relatively
simple method to eliminate and quantify HAMA inter-
ference in CA 125 determinations. Moreover, IgG and
IgM HAMA interference can be separated. Sample dilu-
tion leads to an increase in the minimum detectable
concentration of CA 125 which could be of importance
in samples in the concentration range below 60 kU/I.
Although large scale routine use of this method is
still limited by the extra workload, cost and time in-
volved, it can be used when dealing with samples of
patients suspected to show HAMA, particularly after in
vivo use of monoclonal antibodies for diagnostic or
therapeutic purposes. Moreover, it provides a way to
reanalyse samples on request of a clinician faced with
a clinically discordant assay result that might be a re-
sult of pre-existing HAMA. Furthermore, this proce-
dure is highly suitable for testing new immunoassay
systems for robustness towards HAMA interference.
Testing of HAMA-positive serum samples, before and
after affinity chromatography, with such a new assay
system can give insight into the extent of protection to-
wards HAMA of this new assay procedure. If available,
the results of a non-protected assay system could be
used as a reference method to compare several assay
systems, each being more or less protected against
HAMA interferences.
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